<DOC>
	<DOCNO>NCT00261391</DOCNO>
	<brief_summary>3 patient enrol 3 study cohort . There three cohort give differ , incrementally large dose phase I drug . The safety measure obtain patient . Efficacy measure individualize enrolllees underlie vascular anomaly . The study structure include 24 month drug-phase 24 month follow-up phase . The study close enrollment .</brief_summary>
	<brief_title>Phase I Drug Trial S/E Marimastat Disabling Malformations When Other Options .</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Marimastat</mesh_term>
	<criteria>Patient vascular malformation cause risk one follow base unanimous assessment designate physician multidisciplinary Vascular Anomalies Team . airway/respiratory/visual/auditory/neurologic compromise ; high output cardiac failure ; lifethreatening disable hemorrhage ( cutaneous/GI/intracranial/ parenchymal/cavitary ) ; skeletal distortion/destruction/erosion ; lifethreatening disable soft tissue distortion destruction Patient must felt failed , unable significantly benefit , risk available therapy , include surgery , embolization , sclerotherapy base unanimous assessment designate physician multidisciplinary Vascular Anomalies Team . Patient must felt one physical , imaging , photographic , physiologic measurable feature measure regular basis preliminary evaluation efficacy . The feature ( ) must agree designated physician multidisciplinary Vascular Anomalies Team ) . Signed Patient informed consent . Pregnancy Patient nursing child . Female patient childbearing potential unwilling receive contraceptive counseling use reliable contraceptive method . Patient enrol clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team ) Parent guardian child unwilling provide consent assent .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>Arteriovenous Malformation</keyword>
	<keyword>Lymphatic Malformation</keyword>
	<keyword>Gorham</keyword>
</DOC>